{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:57:31Z","timestamp":1794862651109,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear. Here we use a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures. We compare the antibody-escape maps to similar maps for convalescent polyclonal plasmas, including plasmas from individuals from whom some of the antibodies were isolated. While the binding of polyclonal plasma antibodies are affected by mutations across multiple RBD epitopes, the plasma-escape maps most resemble those of a single class of antibodies that target an epitope on the RBD that includes site E484. Therefore, although the human immune system can produce antibodies that target diverse RBD epitopes, in practice the polyclonal response to infection is skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.<\/jats:p>","DOI":"10.1038\/s41467-021-24435-8","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:04:51Z","timestamp":1625637891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":455,"title":["Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-3349","authenticated-orcid":false,"given":"Allison J.","family":"Greaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6713-6904","authenticated-orcid":false,"given":"Tyler N.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher O.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiska","family":"Weisblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gaebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Agudelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Finkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Muecksch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-0766","authenticated-orcid":false,"given":"Theodora","family":"Hatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-3719","authenticated-orcid":false,"given":"Paul D.","family":"Bieniasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide F.","family":"Robbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-3990","authenticated-orcid":false,"given":"Pamela J.","family":"Bjorkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-3408","authenticated-orcid":false,"given":"Jesse D.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"24435_CR1","unstructured":"Faria, N. R. et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Science. 372, 815\u2013821 (2021)."},{"key":"24435_CR2","doi-asserted-by":"publisher","unstructured":"Voloch, C. M. et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00119-21 (2021).","DOI":"10.1128\/JVI.00119-21"},{"key":"24435_CR3","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jama.2021.1612","volume":"325","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Emergence of a novel SARS-CoV-2 variant in Southern California. J. Am. Med. Assoc. 325, 1324\u20131326 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"24435_CR4","doi-asserted-by":"publisher","unstructured":"West, A. P. et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.02.14.431043 (2021).","DOI":"10.1101\/2021.02.14.431043"},{"key":"24435_CR5","doi-asserted-by":"publisher","unstructured":"Annavajhala, M. K. et al. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.23.21252259 (2021).","DOI":"10.1101\/2021.02.23.21252259"},{"key":"24435_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438\u2013443 (2021).","journal-title":"Nature"},{"key":"24435_CR7","doi-asserted-by":"crossref","unstructured":"Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020).","DOI":"10.7554\/eLife.61312"},{"key":"24435_CR8","doi-asserted-by":"publisher","unstructured":"Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe https:\/\/doi.org\/10.1016\/j.chom.2021.01.014 (2021).","DOI":"10.1016\/j.chom.2021.01.014"},{"key":"24435_CR9","doi-asserted-by":"publisher","unstructured":"Andreano, E. et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.12.28.424451 (2020).","DOI":"10.1101\/2020.12.28.424451"},{"key":"24435_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"24435_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146 (2021).","journal-title":"Nature"},{"key":"24435_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","volume":"27","author":"CK Wibmer","year":"2021","unstructured":"Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622\u2013625 (2021).","journal-title":"Nat. Med."},{"key":"24435_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"24435_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917\u2013924 (2021).","journal-title":"Nat. Med."},{"key":"24435_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.chom.2021.03.008","volume":"29","author":"A Kuzmina","year":"2021","unstructured":"Kuzmina, A. et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe 29, 522\u2013528 (2021).","journal-title":"Cell Host Microbe"},{"key":"24435_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"24435_CR17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e21 (2020).","journal-title":"Cell"},{"key":"24435_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463\u2013476 (2021).","journal-title":"Cell Host Microbe"},{"key":"24435_CR19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184, 2183\u20132200.e22 (2021).","journal-title":"Cell"},{"key":"24435_CR20","doi-asserted-by":"publisher","unstructured":"Steffen, T. L. et al. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.08.21.261727 (2020).","DOI":"10.1101\/2020.08.21.261727"},{"key":"24435_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"24435_CR22","doi-asserted-by":"publisher","unstructured":"Kemp, S. et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion \u0394H69\/V70. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.12.14.422555 (2020).","DOI":"10.1101\/2020.12.14.422555"},{"key":"24435_CR23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1126\/science.abg5268","volume":"372","author":"WN Voss","year":"2021","unstructured":"Voss, W. N. et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science 372, 1108\u20131112 (2021).","journal-title":"Science"},{"key":"24435_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.abf6950","volume":"371","author":"KR McCarthy","year":"2021","unstructured":"McCarthy, K. R. et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science 371, 1139\u20131142 (2021).","journal-title":"Science"},{"key":"24435_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"24435_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"24435_CR27","doi-asserted-by":"publisher","first-page":"e1009352","DOI":"10.1371\/journal.ppat.1009352","volume":"17","author":"K-YA Huang","year":"2021","unstructured":"Huang, K.-Y. A. et al. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 17, e1009352 (2021).","journal-title":"PLoS Pathog."},{"key":"24435_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"24435_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828\u2013842 (2020).","journal-title":"Cell"},{"key":"24435_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44\u201357 (2021).","journal-title":"Cell Host Microbe"},{"key":"24435_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"24435_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310 (2020).","journal-title":"Cell"},{"key":"24435_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","volume":"371","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850\u2013854 (2021).","journal-title":"Science"},{"key":"24435_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.1097211","volume":"305","author":"DJ Smith","year":"2004","unstructured":"Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371\u2013376 (2004).","journal-title":"Science"},{"key":"24435_CR35","doi-asserted-by":"publisher","unstructured":"Dong, J. et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.01.27.428529 (2021).","DOI":"10.1101\/2021.01.27.428529"},{"key":"24435_CR36","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","volume":"2","author":"TN Starr","year":"2021","unstructured":"Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021).","journal-title":"Cell Rep. Med."},{"key":"24435_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1006\/jmbi.1993.1611","volume":"234","author":"BC Cunningham","year":"1993","unstructured":"Cunningham, B. C. & Wells, J. A. Comparison of a structural and a functional epitope. J. Mol. Biol. 234, 554\u2013563 (1993).","journal-title":"J. Mol. Biol."},{"key":"24435_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/gch2.1018","volume":"1","author":"S Elbe","year":"2017","unstructured":"Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID\u2019s innovative contribution to global health. Glob. Chall. 1, 33\u201346 (2017).","journal-title":"Glob. Chall."},{"key":"24435_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","volume":"29","author":"X Shen","year":"2021","unstructured":"Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529\u2013539 (2021).","journal-title":"Cell Host Microbe"},{"key":"24435_CR40","doi-asserted-by":"publisher","unstructured":"Wang, L. et al. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.02.25.432969 (2021).","DOI":"10.1101\/2021.02.25.432969"},{"key":"24435_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/ni.3680","volume":"18","author":"D Angeletti","year":"2017","unstructured":"Angeletti, D. et al. Defining B cell immunodominance to viruses. Nat. Immunol. 18, 456\u2013463 (2017).","journal-title":"Nat. Immunol."},{"key":"24435_CR42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.it.2018.04.008","volume":"39","author":"D Angeletti","year":"2018","unstructured":"Angeletti, D. & Yewdell, J. W. Understanding and manipulating viral immunity: antibody immunodominance enters center stage. Trends Immunol. 39, 549\u2013561 (2018).","journal-title":"Trends Immunol."},{"key":"24435_CR43","doi-asserted-by":"publisher","unstructured":"Greaney, A. J. et al. The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD. Preprint at bioRxiv https:\/\/doi.org\/10.1126\/scitranslmed.abi9915 (2021).","DOI":"10.1126\/scitranslmed.abi9915"},{"key":"24435_CR44","doi-asserted-by":"publisher","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01294-w (2021).","DOI":"10.1038\/s41591-021-01294-w"},{"key":"24435_CR45","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1126\/science.abd2321","volume":"369","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119\u20131123 (2020).","journal-title":"Science"},{"key":"24435_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384 (2020).","journal-title":"Cell"},{"key":"24435_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","volume":"182","author":"C Kreer","year":"2020","unstructured":"Kreer, C. et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 182, 843\u2013854 (2020).","journal-title":"Cell"},{"key":"24435_CR48","doi-asserted-by":"publisher","unstructured":"Yuan, M. et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science https:\/\/doi.org\/10.1126\/science.abh1139 (2021).","DOI":"10.1126\/science.abh1139"},{"key":"24435_CR49","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"24435_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"24435_CR51","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","volume":"33","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. et al. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Rep. 33, 108274 (2020).","journal-title":"Cell Rep."},{"key":"24435_CR52","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1126\/science.1088166","volume":"301","author":"SR Hamilton","year":"2003","unstructured":"Hamilton, S. R. et al. Production of complex human glycoproteins in yeast. Science 301, 1244\u20131246 (2003).","journal-title":"Science"},{"key":"24435_CR53","doi-asserted-by":"publisher","unstructured":"Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell https:\/\/doi.org\/10.1016\/j.cell.2021.04.025 (2021).","DOI":"10.1016\/j.cell.2021.04.025"},{"key":"24435_CR54","unstructured":"Public Health England. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England. (Public Health England, 2021)."},{"key":"24435_CR55","doi-asserted-by":"publisher","unstructured":"de Oliveira, T. et al. A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.03.30.21254323 (2021).","DOI":"10.1101\/2021.03.30.21254323"},{"key":"24435_CR56","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1084\/jem.20141050","volume":"211","author":"F Klein","year":"2014","unstructured":"Klein, F. et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211, 2361\u20132372 (2014).","journal-title":"J. Exp. Med."},{"key":"24435_CR57","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.immuni.2019.04.014","volume":"50","author":"T Schoofs","year":"2019","unstructured":"Schoofs, T. et al. Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope. Immunity 50, 1513\u20131529 (2019).","journal-title":"Immunity"},{"key":"24435_CR58","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 218, e20201993 (2021).","DOI":"10.1101\/2020.09.15.298067"},{"key":"24435_CR59","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B beta coronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"24435_CR60","doi-asserted-by":"publisher","first-page":"E7550","DOI":"10.1073\/pnas.1804015115","volume":"115","author":"J Otwinowski","year":"2018","unstructured":"Otwinowski, J., McCandlish, D. M. & Plotkin, J. B. Inferring the shape of global epistasis. Proc. Natl Acad. Sci. USA 115, E7550\u2013E7558 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24435_CR61","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evolution 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evolution"},{"key":"24435_CR62","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.21105\/joss.02353","volume":"5","author":"S Hilton","year":"2020","unstructured":"Hilton, S. et al. dms-view: interactive visualization tool for deep mutational scanning data. J. Open Source Softw. 5, 2353 (2020).","journal-title":"J. Open Source Softw."},{"key":"24435_CR63","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/bioinformatics\/btl461","volume":"22","author":"BJ Grant","year":"2006","unstructured":"Grant, B. J., Rodrigues, A. P. C., ElSawy, K. M., McCammon, J. A. & Caves, L. S. D. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22, 2695\u20132696 (2006).","journal-title":"Bioinformatics"},{"key":"24435_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24435-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:32:29Z","timestamp":1669969949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24435-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["24435"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-24435-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.17.435863","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Subsequent to completion and submission of the initial version of this study, J.D.B. began consulting for Moderna on viral evolution and epidemiology. J.D.B. has the potential to receive a share of IP revenue as an inventor on a Fred Hutch optioned technology\/patent (application WO2020006494) related to deep mutational scanning of viral proteins. The Rockefeller University has filed a provisional patent application related to SARS-CoV-2 monoclonal antibodies on which D.F.R. and M.C.N. are inventors. The Rockefeller University has applied for a patent relating to the replication-competent VSV\/SARS-CoV-2 chimeric virus on which Y.W, F.S., T.H. and P.B. are inventors (US patent 63\/036,124). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4196"}}